Partnering opportunities
The Walter and Eliza Hall Institute (WEHI) has more than 300 projects in immunology, cancer and infectious disease feeding into its discovery and development pipelines. We are committed to translation of our discoveries into improvements in disease diagnosis, prevention and treatment and have a strong track record of successful development projects with both the private and public sectors.
We have a portfolio of projects potentially available for licensing or collaboration, that includes enabling technologies, drug targets, chemical and biological agents with proof of efficacy, through to projects in Phase II clinical development.
Available opportunities
Contact
For more information about these or other partnering opportunities contact:
|
Dr Julian Clark |
Dr James Dromey Business Development Manager Tel: +61 3 9345 2542 Email: .(JavaScript must be enabled to view this email address) |
Cancer
Novel anti-cancer agent (lead optimisation)
- G2/M cell cycle inhibitor with a novel target and unique mechanism of action
- In vivo efficacy in models of colorectal, brain and lung cancer
More information: Novel anti-cancer agent (lead optimisation) (pdf)
SRC kinase inhibitors for the treatment of colon cancer and other solid tumours (lead optimisation)
- Validated anti-cancer target with a role in tumour progression
- Potent lead compound with a selective kinase profile
- In vivo efficacy in a colorectal cancer model (single agent and in combination)
More information: SRC kinase inhibitors for colon cancer / solid tumours (lead optimisation) (pdf)
Novel platform for targeting IGF-1R in cancer (hit-to-lead)
- “Druggable” site on extracellular surface of IGF-1R
- Suitable for targeting by small molecules
- Offers advantages over antibody- and tyrosine kinase inhibitor-based strategies
More information: Novel platform for targeting IGF-1R in cancer (hit-to-lead) (pdf)
New approaches to breast cancer
- Gene expression profiling of epithelial cell subsets in breast
- Correlation of profiles with breast cancer subtypes
- Potential for greater accuracy in diagnosis and prognosis of breast cancer and possibility for development of new therapies
More information: New approaches to breast cancer (pdf)
Back to top
Immunology
Modulators of B lymphocytes (hit-to-lead)
- Small molecule modulators of B lymphocyte function
- Applications in immunodeficiency, cancer, autoimmune and infectious disease
More information: Modulators of B lymphocytes (hit-to-lead) (pdf)
Immunomodulation by inhibiting antigen cross-presentation (hit-to-lead)
- Novel inhibitors of antigen cross-presentation
- Potential in treating immune-mediated inflammatory diseases and preventing transplant rejection
More information: Immunomodulation by inhibiting antigen cross-presentation (hit-to-lead) (pdf)
Back to top
Infectious diseases
Novel anti-HIV compounds – Frameshift modulators (hit-to-lead)
- Highly conserved HIV target
- Ribosomal frameshifting critical for survival of HIV
- Compounds that modulate HIV frameshifting identified
More information: Novel anti-HIV compounds – Frameshift modulators (hit-to-lead) (pdf)
Anti-fungal compounds (proof-of-concept)
- New classes of anti-fungal compounds identified
- Potent in vitro activity against a broad spectrum of fungi
Back to top
Technology platforms
Modelling and tracking lymphocyte behaviour
- Single cell analysis of lymphocyte differentiation/function
- Modelling of immune responses
- Applications in research and drug discovery
More information: Modelling and tracking lymphocyte behaviour (pdf)
Antibody facility
- Monoclonal/polyclonal antibody production
- In vitro production, testing, conjugation and cell banking
- Immunisation to positive supernatant within 16 weeks
More information: WEHI Antibody Facility (pdf)
High-throughput chemical screening (HTCS) facility
- 250,000 diverse “lead-like” small molecules
- Biochemical and cellular assays, high content imaging, mechanism of action studies and multiplexed biomarker detection available
More information: WEHI High-throughput chemical screening (HTCS) facility (pdf)
Back to top
Other
Novel anti-apoptotic agents (hit-to-lead/lead optimisation)
- Lead compound identified
- Broad therapeutic potential
- Proof-of-principle in mouse models
More information: Novel anti-apoptotic agents (hit-to-lead/lead optimisation) (pdf)
BACE Therapeutics (hit-to-lead)
- Beta secretase inhibitors for the treatment of Alzheimer’s disease and traumatic brain injury
- Two compound classes demonstrated to inhibit beta secretase
Preventing chemotherapy-induced infertility
- Targeting the BH3-only proteins PUMA and NOXA to protect fertility in females during chemotherapy
- Fertility rescued by ablation of PUMA or PUMA/NOXA in a murine model
More information: Preventing chemotherapy-induced infertility (pdf)